InvestorsHub Logo
icon url

zj3001

09/23/21 8:53 PM

#127998 RE: foxi #127995

If I’m right with my assumptions of focusing on Clone3, it will be a guarantee that it will be talked about the most on the James Hicks interview. ITV-1 will briefly make an appearance but won’t be the main show as they will like want to not talk about much more until lawsuit is finished. In addition, the interview with focus on Covid.

I didn’t buy into this company for ITV-1. The real deal is the recombinant Clone3 mAbs.

The only thing that has me sticking it out here is the blueprint to fight infectious diseases with use to AI and mAbs. The valuation of HIV and Covid alone are billions. I see other plays that can yield good returns, but I’m heavily invested and think it can pop to extraordinary returns by year end or first quarter of 2022.

Hindsight is 20/20. Hope I didn’t make a mistake by not flipping. I’m more of a buy and come back a year later kind of guy.

Good luck